AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Veracyte, Inc.
Video analysis: VCYT
All videosNo video analysis for this stock yet. Request one from our team.
News: VCYT
Concurrent Investment Advisors LLC Takes Position in Veracyte, Inc. $VCYT
Concurrent Investment Advisors LLC bought a new position in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent filing with the SEC. The firm bought 17,644 shares of the biotechnology company's stock, valued at approximately $1,036,000. Several other hedge funds have also bought and sold shares of the business.
Veracyte Inc (VCYT) Shares Surge 3.3% -- What GF Score of 81 Tells Investors
On September 09, 2026, Veracyte Inc (VCYT) shares rose 3.3% to $43.85, reflecting a slight uptick amid a challenging price performance over the past month, whic
3 Medical Instruments Stocks Banking on GenAI to Tackle Industry Woes
GenAI offers growth potential for VCYT, GMED and UFPT, but regulatory and technology risks are likely to challenge adoption across healthcare.
Veracyte to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 7:00 a.m. Eastern Time.
Canada Pension Plan Investment Board Purchases Shares of 20,700 Veracyte, Inc. $VCYT
Canada Pension Plan Investment Board bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 20,700 shares of the biotechnology company's stock, valued at approximately $1,216,000. Several other hedge funds and
Connor Clark & Lunn Investment Management Ltd. Takes $1.58 Million Position in Veracyte, Inc. $VCYT
Connor Clark and Lunn Investment Management Ltd. bought a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent disclosure with the SEC. The firm bought 26,948 shares of the biotechnology company's stock, valued at approximately $1,583,000. Other hedge funds and other institutional investors have also recently
Bamco Inc. NY Invests $38.22 Million in Veracyte, Inc. $VCYT
Bamco Inc. NY purchased a new stake in Veracyte, Inc. (NASDAQ: VCYT) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 650,686 shares of the biotechnology company's stock, valued at approximately $38,215,000. Bamco Inc. NY owned approximately 0.81% of Veracyte at the
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
